Two Sigma Advisers LP purchased a new stake in shares of Hill-Rom Holdings, Inc. (NYSE:HRC) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 205,813 shares of the medical technology company’s stock, valued at approximately $17,348,000. Two Sigma Advisers LP owned approximately 0.31% of Hill-Rom at the end of the most recent quarter.
Other hedge funds have also recently made changes to their positions in the company. Principal Financial Group Inc. boosted its stake in shares of Hill-Rom by 8.5% during the third quarter. Principal Financial Group Inc. now owns 283,290 shares of the medical technology company’s stock valued at $20,963,000 after purchasing an additional 22,188 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Hill-Rom by 52.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,357 shares of the medical technology company’s stock worth $283,000 after acquiring an additional 1,156 shares during the period. Magnetar Financial LLC lifted its stake in shares of Hill-Rom by 24.4% in the third quarter. Magnetar Financial LLC now owns 17,458 shares of the medical technology company’s stock worth $1,292,000 after acquiring an additional 3,421 shares during the period. Public Employees Retirement System of Ohio lifted its stake in shares of Hill-Rom by 43.7% in the third quarter. Public Employees Retirement System of Ohio now owns 56,022 shares of the medical technology company’s stock worth $4,146,000 after acquiring an additional 17,035 shares during the period. Finally, Wedge Capital Management L L P NC lifted its stake in shares of Hill-Rom by 4.0% in the fourth quarter. Wedge Capital Management L L P NC now owns 209,190 shares of the medical technology company’s stock worth $17,633,000 after acquiring an additional 8,095 shares during the period. 82.50% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts recently commented on HRC shares. Barclays reaffirmed a “buy” rating and issued a $100.00 price objective on shares of Hill-Rom in a research note on Wednesday, January 10th. Zacks Investment Research lowered Hill-Rom from a “buy” rating to a “hold” rating in a research note on Monday, January 15th. Needham & Company LLC reaffirmed a “buy” rating and issued a $105.00 price objective (up from $90.00) on shares of Hill-Rom in a research note on Tuesday, January 16th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $92.00 price objective on shares of Hill-Rom in a research note on Wednesday, November 29th. Finally, KeyCorp reaffirmed a “buy” rating and issued a $94.00 price objective on shares of Hill-Rom in a research note on Thursday, December 21st. Five investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $95.38.
Shares of HRC stock opened at $87.18 on Wednesday. The firm has a market capitalization of $5,704.84, a P/E ratio of 21.39, a price-to-earnings-growth ratio of 1.39 and a beta of 1.03. The company has a quick ratio of 1.29, a current ratio of 1.75 and a debt-to-equity ratio of 1.39. Hill-Rom Holdings, Inc. has a 1-year low of $68.52 and a 1-year high of $91.11.
Hill-Rom (NYSE:HRC) last issued its earnings results on Friday, January 26th. The medical technology company reported $0.92 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.79 by $0.13. The business had revenue of $669.70 million during the quarter, compared to the consensus estimate of $670.00 million. Hill-Rom had a return on equity of 20.24% and a net margin of 7.14%. The firm’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same period in the previous year, the company posted $0.75 earnings per share. equities analysts anticipate that Hill-Rom Holdings, Inc. will post 4.62 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, March 30th. Shareholders of record on Friday, March 23rd will be issued a $0.20 dividend. This is an increase from Hill-Rom’s previous quarterly dividend of $0.18. This represents a $0.80 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date is Thursday, March 22nd. Hill-Rom’s payout ratio is presently 24.49%.
TRADEMARK VIOLATION NOTICE: This article was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.dispatchtribunal.com/2018/03/21/two-sigma-advisers-lp-takes-17-35-million-position-in-hill-rom-holdings-inc-hrc.html.
Hill-Rom Holdings, Inc is a global medical technology company. The Company partners with health care providers across care settings, by focusing on patient care solutions that improve clinical and economic outcomes in five core areas: advancing mobility, wound care and prevention, patient monitoring and diagnostics, surgical safety and efficiency and respiratory health.
Want to see what other hedge funds are holding HRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hill-Rom Holdings, Inc. (NYSE:HRC).
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.